SEC Tracker
Get the app
LFCR · XBRL financial data

Lifecore Biomedical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (LFCR's year ends in late December)

In thousands of dollarsNov 26, 2023Feb 25, 2024May 26, 2024Aug 25, 2024Nov 24, 2024Feb 23, 2025May 25, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cost of goods and services sold20,19323,81020,614*19,31821,48025,30922,46223,318—18,73122,09218,496
Gross profit9,95711,894—5,38711,0849,84513,9827,791—4,46212,0756,826
Research and development2,0982,1702,161*2,1861,9242,0452,1031,963—1,2171,5371,421
Selling, general and administrative9,1859,84812,224*14,78511,11910,0938,9808,895—7,9177,9716,299
Total operating expenses11,44012,78915,123*16,97113,043———————
Operating income (loss)(1,483)(895)2,149*(11,584)(1,959)(9,029)5,327(3,067)—(4,672)2,567(894)
Interest income——year only15—10820658—128144232
Interest expense—4,2895,848*5,383—5,4815,7276,384—7,3487,7518,100
Other income (expense)(967)(814)(1,102)*(203)(304)333171110—110110(1)
Income tax expense (benefit)(65)217(57)*(25)43(8)33333—432351
Net income (loss)14,21815,632(7,083)*(16,230)(6,571)(14,769)(1,147)(9,991)—(14,980)(6,156)(40,084)
Earnings per share, basic USD per share0.470.51(0.23)*(0.53)(0.25)(0.47)(0.06)(0.29)—(0.43)(0.19)(1.08)
Earnings per share, diluted USD per share0.390.42(0.16)*(0.53)(0.25)(0.47)(0.06)(0.29)—(0.43)(0.19)(1.08)
Weighted average shares, basic thousands of shares30,45830,48830,547*30,85634,36137,02137,00837,403—37,47737,57537,845
Weighted average shares, diluted thousands of shares36,41936,60943,201*30,85634,36137,02137,00837,403—37,47737,57537,845

Balance sheet

CSV

Fiscal quarters (LFCR's year ends in late December)

In thousands of dollarsNov 26, 2023Feb 25, 2024May 26, 2024Aug 25, 2024Nov 24, 2024Feb 23, 2025May 25, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents3,2213,0738,4625,5209,4555,4178,26518,85617,46920,79517,24123,035
Accounts receivable——31,15325,14530,303———————
Inventory41,44639,67039,97941,64239,21434,59632,29133,80129,08528,15525,47527,695
Prepaid and other current assets1,8451,9691,4391,8762,8862,5481,4542,1381,9211,8032,9522,604
Total current assets76,71476,15781,03374,18381,85884,21185,67783,92882,29277,63983,69184,681
Property and equipment, net142,913145,367148,598148,756150,576128,223129,006128,575127,304125,513123,714122,040
Right-of-use asset4,0362,5102,4422,3732,3042,233——————
Goodwill13,88113,88113,88113,88113,88113,88113,88113,88113,88113,88113,88113,881
Total assets245,816246,241253,960246,824255,386237,693239,342235,204232,177225,499229,500228,303
Accounts payable19,02315,68516,33418,01014,9677,4058,22010,1155,8397,0147,5348,587
Accrued liabilities——22,538——19,74521,95819,84317,73413,48314,10713,453
Current portion of long-term debt7737737737737739303,437947954962970978
Total current liabilities40,25436,81038,87240,52335,29031,11630,17829,95823,57320,49721,64122,040
Long-term debt92,08596,336100,819105,545110,528———————
Lease liability, non-current——1,729——1,4361,3431,2141,1201,025928831
Total liabilities203,471186,807200,058207,321195,626190,267191,909198,418198,117204,721213,407250,579
Accumulated deficit(175,072)(159,440)(166,523)(182,753)(191,456)(204,093)(205,240)(218,095)(223,201)(238,181)(244,337)(284,421)
Total stockholders' equity1,42117,68611,315(3,938)15,4492,2291,336(10,537)(14,202)(28,438)(34,094)(73,404)
Total liabilities and equity245,816246,241253,960246,824255,386237,693239,342235,204232,177225,499229,500228,303
Common shares outstanding (cover page) thousands of shares30,87030,87030,89830,89837,02537,02537,40837,46637,47737,50937,85337,906

Cash flows

CSV

Fiscal quarters (LFCR's year ends in late December)

In thousands of dollarsNov 26, 2023Feb 25, 2024May 26, 2024Aug 25, 2024Nov 24, 2024Feb 23, 2025May 25, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)14,21815,632(7,083)*(16,230)(6,571)(14,769)(1,147)(9,991)—(14,980)(6,156)(40,084)
Stock-based compensation1,577*1,493*1,598*2,4193,372*2,5521,815*2,392—1,6982,085*1,715*
Depreciation and amortization2,206*2,233*2,252*1,9932,044*2,076*1,914*1,981————
Net cash from operating activities1,006*(1,534)*8,640*(643)(6,110)*1,1995,349*1,762—4,700(2,189)*6,946*
Purchases of property and equipment3,979*6,251*3,111*3,3922,470*5,4562,097*1,737—1,118513*912*
Net cash from investing activities(3,979)*(6,251)*(2,637)*(3,392)(2,470)*1,544(2,097)*(1,737)—(1,118)(513)*(912)*
Proceeds from issuing common stock—(724)*0*123,840*17*(8)*0————
Repayments of long-term debt193*193*(386)*—————————
Net cash from financing activities(2,448)*7,637*(614)*1,09312,515*(6,783)(402)*(1,388)—(256)(852)*(240)*
Net change in cash(5,421)*(148)*5,389*(2,942)3,935*(4,040)2,850*(1,363)—3,326(3,554)*5,794*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Lifecore Biomedical23,03525,3226,946*37.9M— 10-QSep 30, 2026
Precigen16,32954,978(17,809)*358.0M2.1 quarters 10-QJun 30, 2026
SELLAS Life Sciences Group138,343not reported(7,588)*201.9M18.2 quarters 10-QJun 30, 2026
Sagimet Biosciences165,896not reported(11,099)*not reported21.6 quarters 10-QJun 30, 2026
Aldeyra Therapeutics45,090not reported(4,589)*60.3M9.8 quarters 10-QJun 30, 2026
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Heron Therapeutics20,721not reported(2,213)*189.9M19.3 quarters 10-QJun 30, 2026
Natures Sunshine Products82,503116,985835*17.6M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.